Stocks fell and small caps slumped Wednesday as the 30-year Treasury yield hit 5.7%, a 24-year high,

Amazon, Alphabet and Tesla rose Friday, but Robinhood traders sold all three. The monthly data sugge

Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast an

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closi

AstraZeneca & Daiichi Sankyo team up with Summit Therapeutics to test Datroway + ivonescimab com

Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Typ

Robinhood traders just recorded their biggest five-day buying binge ever, piling into stocks includi

Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Equal-Weight and

Nasdaq 100 gains as softer PCE inflation cools Fed rate-hike bets, with oil above $91 and Micron ear

Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and ra

AstraZeneca buys $2 billion in Summit Therapeutics equity to test ivonescimab with ADCs, providing c

Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-mar

Navitas jumped 11.8% after winning a U.S. 10kV SiC program; BIO-key led gainers, while NewGenIvf and

https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-equity-investment

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) f

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featurin

A fourth straight decline in crude oil handed Wall Street a fresh leg higher Monday, with the Nasdaq

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the

Summit partner Akeso reports 30.8-month median OS for ivonescimab vs 22.6 for pembrolizumab in lung

Ivonescimab Reduced the Risk of Death by 27% Compared to PembrolizumabHARMONi-2 Demonstrated an Impr

Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics (NASDAQ:SMMT) from Hold to Buy and

Stocks rallied and Treasury yields retreated from three-year highs after Fed Governor Waller signale

Summit Therapeutics' partner Akeso reported positive overall survival results for ivonescimab in

U.S. stocks rose Thursday; Summit Therapeutics jumped 10.1% after Phase III results, while Snowflake

Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced positive ov

Summit Therapeutics partner Akeso Phase 3 HARMONi-GI1 trial shows ivonescimab outperforms durvalumab

Nasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. E

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) f

Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced positive to

Summit Therapeutics reported positive Phase 3 trial results for ivonescimab, extending progression-f

Top analysts upgraded Fluence Energy, Dynatrace, and Advanced Micro Devices, Check out their ratings

Bernstein analyst Jeffrey Walch upgrades Summit Therapeutics (NASDAQ:SMMT) from Underperform to M

First Immunotherapy-Based Regimen to Show Statistically Significant and Clinically Meaningful PFS Be

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) f

Leerink Partners analyst Daina Graybosch upgrades Summit Therapeutics (NASDAQ:SMMT) from Underper

HARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Can

"Mad Money" host Jim Cramer recommends buying Carvana and Summit Therapeutics. Reddit "s

Corporate executives say optimistic things about their companies every day. They appear on earnin

Summit Therapeutics beat second-quarter estimates but warned current cash is insufficient to fund op

Stifel analyst Dara Azar maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the pr

Guggenheim analyst Brad Canino maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers

US stock futures higher, Deckers Outdoor shares fall after reporting Q1 results. Other stocks also d

Liquidity, Capital Resources and Going Concern Going Concern During the three and six months ended J

Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.19) per share which beat the anal

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quar